DB:S3F

Stock Analysis Report

Santhera Pharmaceuticals Holding

Executive Summary

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for orphan and other diseases with high unmet medical needs in the European countries.


Snowflake Analysis

High growth potential and slightly overvalued.

Share Price & News

How has Santhera Pharmaceuticals Holding's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: S3F has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

S3F

-2.3%

DE Biotechs

-0.2%

DE Market


1 Year Return

1.3%

S3F

8.4%

DE Biotechs

13.7%

DE Market

Return vs Industry: S3F underperformed the German Biotechs industry which returned 5.3% over the past year.

Return vs Market: S3F underperformed the German Market which returned 17.1% over the past year.


Shareholder returns

S3FIndustryMarket
7 Day0%-2.3%-0.2%
30 Day0%-3.2%0.3%
90 Day1.6%6.3%3.7%
1 Year1.3%1.3%8.6%8.4%17.2%13.7%
3 Year-72.0%-72.0%44.5%42.9%15.4%5.3%
5 Year-80.1%-80.1%13.0%10.6%21.3%4.7%

Price Volatility Vs. Market

How volatile is Santhera Pharmaceuticals Holding's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Santhera Pharmaceuticals Holding undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: S3F (€13.64) is trading below our estimate of fair value (€1081.57)

Significantly Below Fair Value: S3F is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: S3F is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: S3F is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate S3F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: S3F is overvalued based on its PB Ratio (15.2x) compared to the DE Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Santhera Pharmaceuticals Holding forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

61.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: S3F is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).

Earnings vs Market: S3F is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: S3F's is expected to become profitable in the next 3 years.

Revenue vs Market: S3F's revenue (53.3% per year) is forecast to grow faster than the German market (4.8% per year).

High Growth Revenue: S3F's revenue (53.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if S3F's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Santhera Pharmaceuticals Holding performed over the past 5 years?

-46.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: S3F is currently unprofitable.

Growing Profit Margin: S3F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: S3F is unprofitable, and losses have increased over the past 5 years at a rate of -46% per year.

Accelerating Growth: Unable to compare S3F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: S3F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: S3F has a negative Return on Equity (-580.67%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Santhera Pharmaceuticals Holding's financial position?


Financial Position Analysis

Short Term Liabilities: S3F's short term assets (CHF38.5M) exceed its short term liabilities (CHF27.2M).

Long Term Liabilities: S3F's short term assets (CHF38.5M) do not cover its long term liabilities (CHF69.6M).


Debt to Equity History and Analysis

Debt Level: S3F's debt to equity ratio (649.6%) is considered high.

Reducing Debt: Insufficient data to determine if S3F's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: S3F has a low level of unsold assets or inventory.

Debt Coverage by Assets: S3F's debt is not covered by short term assets (assets are 0.6x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: S3F has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: S3F has less than a year of cash runway if free cash flow continues to reduce at historical rates of -26.9% each year


Next Steps

Dividend

What is Santhera Pharmaceuticals Holding's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate S3F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate S3F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if S3F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if S3F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of S3F's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.4yrs

Average management tenure


CEO

Thomas Meier (57yo)

7.9yrs

Tenure

CHF960,849

Compensation

Dr. Thomas Meier, Ph.D., has been the Chief Executive Officer of Santhera Pharmaceuticals Holding AG since October 1, 2011 and also serves as its Head of Executive Management Team. Dr. Meier served as the  ...


CEO Compensation Analysis

Compensation vs Market: Thomas's total compensation ($USD972.85K) is above average for companies of similar size in the German market ($USD425.50K).

Compensation vs Earnings: Thomas's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Thomas Meier
CEO, Head of Executive Management Team & Director7.9yrsCHF960.85k0.71% CHF942.6k
Christoph Rentsch
CFO & EVP4.2yrsno datano data
Oliver Strub
Executive VP4.6yrsno datano data
Günther Metz
Head of Business Development & Executive VP0yrsno datano data
Kristina Nygren
Executive VP2.7yrsCHF1.24mno data

4.4yrs

Average Tenure

58yo

Average Age

Experienced Management: S3F's management team is considered experienced (4.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Thomas Meier
CEO, Head of Executive Management Team & Director7.9yrsCHF960.85k0.71% CHF942.6k
Martin Gertsch
Vice Chairman0yrsCHF274.28k0.34% CHF452.4k
Patrick Vink
Director2.4yrsCHF219.42k0.0090% CHF11.9k
Elmar Schnee
Chairman2.4yrsCHF296.31k0.11% CHF142.5k
Philipp Gutzwiller
Director2.4yrsCHF208.46k0.064% CHF84.3k

2.4yrs

Average Tenure

56yo

Average Age

Experienced Board: S3F's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 43.6%.


Top Shareholders

Company Information

Santhera Pharmaceuticals Holding AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Santhera Pharmaceuticals Holding AG
  • Ticker: S3F
  • Exchange: DB
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CHF143.335m
  • Listing Market Cap: CHF131.905m
  • Shares outstanding: 11.11m
  • Website: https://www.santhera.com

Number of Employees


Location

  • Santhera Pharmaceuticals Holding AG
  • Hohenrainstrasse 24
  • Pratteln
  • Basel-Landschaft
  • 4133
  • Switzerland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SANNSWX (SIX Swiss Exchange)YesRegistered SharesCHCHFNov 2006
S3FDB (Deutsche Boerse AG)YesRegistered SharesDEEURNov 2006
SPHD.FOTCPK (Pink Sheets LLC)YesRegistered SharesUSUSDNov 2006
0QN1LSE (London Stock Exchange)YesRegistered SharesGBCHFNov 2006

Biography

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for orphan and other diseases with high unmet medical needs in the European countries. The company’s portfolio comprises clinical stage and marketed treatments for neuroophthalmologic, neuromuscular, and pulmonary diseases. Its pipeline product, idebenone, is in Phase III clinical stage for the treatment of Duchenne muscular dystrophy. The company commercializes idebenone under the Raxone name in 20 countries. Its pipeline also includes omigapil, an investigational drug with anti-apoptotic properties in development to address unmet medical needs for patients with congenital muscular dystrophy; and POL6014, a clinical stage selective inhibitor of human neutrophil elastase to treat cystic fibrosis and other lung diseases. Santhera Pharmaceuticals Holding AG is headquartered in Pratteln, Switzerland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/25 21:18
End of Day Share Price2019/06/28 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.